ESC 2020: Eli Lilly and Boehringer Ingelheim’s Jardiance Presents Positive Data Demonstrating Risk Reduction in Hospitalization from Heart Failure

The EMPEROR-reduced Phase III trial for Jardiance demonstrated risk reduction in hospitalization due to HF for patients with or without Type 2 Diabetes. Credit: i viewfinder via Shutterstock.